PDCD1 and neoplasm: Since a blockade of the PD-1/PD-L1 signaling pathway may restore the native T-cell mediated tumor response, leading to tumor regression [18], in the last few years, an increasing number of immune checkpoint inhibitors (ICI) have been developed and applied in the management of different types of cancers [19].